Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Aminolab Co. Ltd. currently has 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This application is being examined by 1 distinct examiner, BOECKELMAN, JACOB A, who is the busiest examiner for the portfolio. The matter is being handled within 1 distinct art unit, which indicates the technical focus of the current application.
With BOECKELMAN, JACOB A handling 1 pending office action, the company's interaction with the patent office is limited to the 1 distinct examiner. This concentration allows for a prosecution strategy tailored to the specific requirements of the examiner. The presence of 1 distinct art unit further shows that the pending workload is not dispersed across different sections of the patent office.
The data shows a prosecution profile where the metrics for distinct examiners and art units are limited. This structure means that the outcome of the 1 pending office action will determine the company's immediate success in the Biotechnology & Pharmaceuticals sector. The current prosecution structure allows for a direct approach to addressing rejections or objections raised during the review of the 1 pending office action.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| BOECKELMAN, JACOB A | 1 | 35.2% | +45.6% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18705308 | METHOD FOR PRODUCTION OF BIOACTIVE SUBSTANCE USING BLOOD AND APPLICATION THEREOF | BOECKELMAN, JACOB A | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18705308 | METHOD FOR PRODUCTION OF BIOACTIVE SUBSTANCE USING BLOOD AND APPLICATION THEREOF | BOECKELMAN, JACOB A | — |
| Art Unit | Apps |
|---|---|
| 1655 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18705308 | METHOD FOR PRODUCTION OF BIOACTIVE SUBSTANCE USING BLOOD AND APPLICATION THEREOF | BOECKELMAN, JACOB A | 1655 | §103§112 | Non-Final OA | — | Pending | Apr 26, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialAminolab Co. Ltd. has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Jacob A Boeckelman has the most, with 1 of Aminolab Co. Ltd.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.